Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Funding round brings in additional $3M for fibrotic disease drugmaker
Promedior, a developer of fibrotic disease treatments, raised an additional $3 million from Shire Strategic Investment Group in the second closing of a Series D financing round. The firm will use the proceeds to continue development of its experimental drugs, including its lead candidate, PRM-151, which is in early-stage clinical development for idiopathic pulmonary fibrosis.
Or we can send an email on your behalf